30% of people worldwide suffer from chronic pain, and managing pain via opioids has created a crisis of its own. We’re engineering psychedelics to relieve patient suffering, avoid the prescription of more harmful substances, and reduce the burden on the healthcare system.
In 1968, psychedelic research was shut down for having ‘no therapeutic value’, and only in 2018 was psilocybin designated as a breakthrough therapy for depression. We’re working with key experts to restart clinical research of psychedelics, many of which are being studied for the first time.
Psychedelics can be made even more effective with modifications. We’re searching through 100,000+ biochemical combinations to identify and optimize the best molecules for treatment, and we’ve only scratched the surface of what is possible.
Cy optimises psychedelics to generate new solutions for chronic pain.
Cy Biopharma AG
Oberneuhofstrasse 6
6340 Baar